<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11355946</article-id><article-id pub-id-type="pmc">2363630</article-id><article-id pub-id-type="pii">6691803</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1803</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schr&#x000f6;der</surname><given-names>C P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wisman</surname><given-names>G B A</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Jong</surname><given-names>S de</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Graaf</surname><given-names>W T A van der</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ruiters</surname><given-names>M H J</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Mulder</surname><given-names>N H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leij</surname><given-names>L F M H de</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Zee</surname><given-names>A G J van der</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Vries</surname><given-names>E G E de</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departments of Medical Oncology,<label>2</label> Gynecologic Oncology,<label>3</label> Pathology and Laboratory Medicine, University Hospital Groningen, The Netherlands</aff><author-notes><fn fn-type="present-address" id="note1"><p>CP Schr&#x000f6;der and GBA Wisman contributed equally to this work. Thisstudy was supported by grants RUG 96-1277 and 97-1581 of the Dutch Cancer Society.</p></fn></author-notes><pub-date pub-type="ppub"><month>05</month><year>2001</year></pub-date><volume>84</volume><issue>10</issue><fpage>1348</fpage><lpage>1353</lpage><history><date date-type="received"><day>25</day><month>10</month><year>2000</year></date><date date-type="rev-recd"><day>22</day><month>02</month><year>2001</year></date><date date-type="accepted"><day>28</day><month>02</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>High-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT) may accelerate telomere length loss in haematopoietic stem cells. As data including pre-and post-treatment samples are lacking, we studied leukocyte telomere length and telomerase activity before and after treatment in breast cancer patients randomized to receive 5 adjuvant courses FEC (5-FU, epirubicin and cyclophosphamide) (<italic>n</italic>= 17), or 4 &#x000d7; FEC followed by high-dose cyclophosphamide, thiotepa, carboplatin and autologous PBSCT (<italic>n</italic>= 16). Haemoglobin, MCV, leukocyte-and platelet numbers were assessed prior to (<italic>t</italic><sub>0</sub>), 5 months after (<italic>t</italic><sub>1</sub>) and 9 months after chemotherapy (<italic>t</italic><sub>2</sub>); these parameters were decreased at <italic>t</italic><sub>1</sub> and <italic>t</italic><sub>2</sub> compared to <italic>t</italic><sub>0</sub>(high-dose: all parameters; standard-dose: leukocytes and platelets), and all parameters were lower after high-dose than standard-dose treatment at <italic>t</italic><sub>1</sub>. Paired individual leukocyte samples of <italic>t</italic><sub>0</sub> and <italic>t</italic><sub>1</sub> showed telomere length change (determined by telomere restricted fragment (TRF) assay) ranging from +0.8 to &#x02013;2.2&#x02008;kb, with a decreased TRF length in 9 patients of both groups. Telomerase activity (determined by TRAP assay) was below detection limit in leukocyte samples of <italic>t</italic><sub>0</sub> and <italic>t</italic><sub>1</sub>. Thus, standard-and high-dose chemotherapy negatively affect haematological reconstitution in this setting. In individual patients, telomere length can be remarkably changed following haematological proliferative stress after treatment. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.bjcancer.com">www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>breast cancer</kwd><kwd>telomere length</kwd><kwd>high-dose chemotherapy</kwd><kwd>autologous stem cell transplantation</kwd></kwd-group></article-meta></front></article>


